Article

Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccination

2021-04-19

Abstract excerpt

<title>Abstract</title> <p>Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic. mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by a three to four week gap. UK policy in 2021 is to extend the dosing interval from three to twelve weeks and other countries are likely to follow suit given the demand for mRNA vaccines and ongoing uncontrolled transmission. T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8e5ec976-2692-5c43-a73e-1cfc475864dc
DOI: 10.21203/rs.3.rs-428630/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationDOI 10.21203/rs.3.rs-428630/v1Read

Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2Semantic proximity Read

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantSemantic proximity Read

Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccinationSemantic proximity Read

STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity Read

Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)Semantic proximity Read

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged peopleSemantic proximity Read

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort StudySemantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adultsSemantic proximity Read

Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceSemantic proximity Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adultsSemantic proximity Read